ERBB2 and neoplasm: Therefore, in an attempt to predict preferential benefit from combined AKT inhibitor/trastuzumab therapy, exploratory biomarker analyses may need to consider the polygenic nature of trastuzumab resistance and assess multiple aberrations in the HER2 signaling pathway in each tumor.